Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case-cohort.
anticoagulants
coumarins
hemorrhage
pharmacogenetics
single nucleotide polymorphism
Journal
Pharmacotherapy
ISSN: 1875-9114
Titre abrégé: Pharmacotherapy
Pays: United States
ID NLM: 8111305
Informations de publication
Date de publication:
30 Apr 2024
30 Apr 2024
Historique:
revised:
26
03
2024
received:
20
11
2023
accepted:
01
04
2024
medline:
30
4
2024
pubmed:
30
4
2024
entrez:
30
4
2024
Statut:
aheadofprint
Résumé
Major bleeding occurs annually in 1%-3% of patients on vitamin K antagonists (VKAs), despite close monitoring. Genetic variants in proteins involved in VKA response may affect this risk. To determine the association of genetic variants (cytochrome P450 enzymes 2C9 [CYP2C9] and 4F2 [CYP4F2], gamma-glutamyl carboxylase [GGCX]) with major bleeding in VKA users, separately and combined, including vitamin K epoxide reductase complex subunit-1 (VKORC1). A case-cohort study was established within the BLEEDS cohort, which includes 16,570 patients who initiated VKAs between 2012 and 2014. We selected all 326 major bleeding cases that occurred during 17,613 years of follow-up and a random subcohort of 978 patients. We determined variants in CYP2C9, CYP4F2, GGCX, VKORC1 and evaluated the interaction between variant genotypes. Hazard ratios for major bleeding with 95% confidence intervals (95% CI) were estimated by weighted Cox regression. Genotype was determined in 256 cases and 783 subcohort members. Phenprocoumon was the most prescribed VKA for both cases and the subcohort (78% and 75%, respectively). Patients with major bleeding were slightly older than subcohort patients. CYP4F2-TT carriership was associated with a 1.6-fold (95% CI 0.9-2.8) increased risk of major bleeding compared with CC-alleles, albeit not statistically significant. For the CYP2C9 and GGCX variants instead, the major bleeding risk was around unity. Carrying at least two variant genotypes in CYP2C9 (poor metabolizer), CYP4F2-TT, and VKORC1-AA was associated with a 4.0-fold (95%CI 1.4-11.4) increased risk, while carriers of both CYP4F2-TT and VKORC1-AA had a particularly increased major bleeding risk (hazard ratio 6.7, 95% CI 1.5-29.8) compared with carriers of CC alleles in CYP4F2 and GG in VKORC1. However, the number of major bleeding cases in carriers of multiple variants was few (8 and 5 patients, respectively). CYP4F2 polymorphism was associated with major bleeding, especially in combination with VKORC1 genetic variants. These variants could be considered to further personalize anticoagulant treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Major bleeding occurs annually in 1%-3% of patients on vitamin K antagonists (VKAs), despite close monitoring. Genetic variants in proteins involved in VKA response may affect this risk.
AIM
OBJECTIVE
To determine the association of genetic variants (cytochrome P450 enzymes 2C9 [CYP2C9] and 4F2 [CYP4F2], gamma-glutamyl carboxylase [GGCX]) with major bleeding in VKA users, separately and combined, including vitamin K epoxide reductase complex subunit-1 (VKORC1).
METHODS
METHODS
A case-cohort study was established within the BLEEDS cohort, which includes 16,570 patients who initiated VKAs between 2012 and 2014. We selected all 326 major bleeding cases that occurred during 17,613 years of follow-up and a random subcohort of 978 patients. We determined variants in CYP2C9, CYP4F2, GGCX, VKORC1 and evaluated the interaction between variant genotypes. Hazard ratios for major bleeding with 95% confidence intervals (95% CI) were estimated by weighted Cox regression.
RESULTS
RESULTS
Genotype was determined in 256 cases and 783 subcohort members. Phenprocoumon was the most prescribed VKA for both cases and the subcohort (78% and 75%, respectively). Patients with major bleeding were slightly older than subcohort patients. CYP4F2-TT carriership was associated with a 1.6-fold (95% CI 0.9-2.8) increased risk of major bleeding compared with CC-alleles, albeit not statistically significant. For the CYP2C9 and GGCX variants instead, the major bleeding risk was around unity. Carrying at least two variant genotypes in CYP2C9 (poor metabolizer), CYP4F2-TT, and VKORC1-AA was associated with a 4.0-fold (95%CI 1.4-11.4) increased risk, while carriers of both CYP4F2-TT and VKORC1-AA had a particularly increased major bleeding risk (hazard ratio 6.7, 95% CI 1.5-29.8) compared with carriers of CC alleles in CYP4F2 and GG in VKORC1. However, the number of major bleeding cases in carriers of multiple variants was few (8 and 5 patients, respectively).
CONCLUSIONS
CONCLUSIONS
CYP4F2 polymorphism was associated with major bleeding, especially in combination with VKORC1 genetic variants. These variants could be considered to further personalize anticoagulant treatment.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Center for Translational Molecular Medicine
Organisme : Hartstichting
Organisme : Trombosestichting Nederland
Informations de copyright
© 2024 The Authors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy published by Wiley Periodicals LLC on behalf of Pharmacotherapy Publications, Inc.
Références
Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S‐e88S. doi:10.1378/chest.11-2292
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio‐Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373‐498. doi:10.1093/eurheartj/ehaa612
Rang HP. In: Ritter JM, Flower RJ, Henderson G, Dale MM, eds. Rang and Dale's Pharmacology. Eighth ed., main edition. ed Elsevier Churchill Livingstone; 2015.
Linkins LA. Bleeding risks associated with vitamin K antagonists. Blood Rev. 2013;27(3):111‐118. doi:10.1016/j.blre.2013.02.004
van Rein N, Lijfering WM, Bos MH, et al. Objectives and design of BLEEDS: a cohort study to identify new risk factors and predictors for major bleeding during treatment with vitamin K antagonists. PLoS One. 2016;11(12):e0164485. doi:10.1371/journal.pone.0164485
Marín F, González‐Conejero R, Capranzano P, Bass Theodore A, Roldán V, Angiolillo Dominick J. Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol. 2009;54(12):1041‐1057. doi:10.1016/j.jacc.2009.04.084
Baker WL, Johnson SG. Pharmacogenetics and oral antithrombotic drugs. Curr Opin Pharmacol. 2016;27:38‐42. doi:10.1016/j.coph.2016.01.008
Teichert M, Eijgelsheim M, Uitterlinden AG, et al. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes. Pharmacogenet Genomics. 2011;21(1):26‐34. doi:10.1097/FPC.0b013e32834154fb
Bryk AH, Wypasek E, Plens K, Awsiuk M, Undas A. Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: association with increased number of single nucleotide polymorphisms. Vasc Pharmacol. 2018;106:22‐27. doi:10.1016/j.vph.2018.02.002
Kawai VK, Cunningham A, Vear SI, et al. Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics. 2014;15(16):1973‐1983. doi:10.2217/pgs.14.153
Lund K, Gaffney D, Spooner R, Etherington AM, Tansey P, Tait RC. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin international normalized ratio control and bleeding rates. Br J Haematol. 2012;158(2):256‐261. doi:10.1111/j.1365-2141.2012.09150.x
Misasi S, Martini G, Paoletti O, et al. VKORC1 and CYP2C9 polymorphisms related to adverse events in case‐control cohort of anticoagulated patients. Medicine (Baltimore). 2016;95(52):e5451. doi:10.1097/md.0000000000005451
Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Büller HR. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med. 2005;2(10):e312. doi:10.1371/journal.pmed.0020312
Limdi NA, McGwin G, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African‐American and European‐American patients on warfarin. Clin Pharmacol Ther. 2008;83(2):312‐321. doi:10.1038/sj.clpt.6100290
Roth JA, Boudreau D, Fujii MM, et al. Genetic risk factors for major bleeding in patients treated with warfarin in a community setting. Clin Pharmacol Ther. 2014;95(6):636‐643. doi:10.1038/clpt.2014.26
Ma C, Zhang Y, Xu Q, et al. Influence of warfarin dose‐associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin. Int J Hematol. 2012;96(6):719‐728. doi:10.1007/s12185-012-1205-8
Varnai R, Sipeky C, Nagy L, Balogh S, Melegh B. CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary. Environ Toxicol Pharmacol. 2017;56:282‐289. doi:10.1016/j.etap.2017.10.003
van Rein N, Cannegieter SC, Rosendaal FR, Reitsma PH, Lijfering WM. Suspected survivor bias in case–control studies: stratify on survival time and use a negative control. J Clin Epidemiol. 2014;67(2):232‐235. doi:10.1016/j.jclinepi.2013.05.011
Sun Y, Wu Z, Li S, et al. Impact of gamma‐glutamyl carboxylase gene polymorphisms on warfarin dose requirement: a systematic review and meta‐analysis. Thromb Res. 2015;135(4):739‐747. doi:10.1016/j.thromres.2015.01.029
Liang R, Wang C, Zhao H, Huang J, Hu D, Sun Y. Influence of CYP4F2 genotype on warfarin dose requirement–a systematic review and meta‐analysis. Thromb Res. 2012;130(1):38‐44. doi:10.1016/j.thromres.2011.11.043
van Heteren DM, Lijfering WM, van der Meer FJM, et al. Association of VKORC1 polymorphisms and major bleedings in patients who are treated with vitamin K antagonists. J Intern Med. 2023;293(1):124‐127. doi:10.1111/joim.13569
Lash TL, VanderWeele TJ, Haneause S, Rothman KJ. Chapter 7: Case‐Control Studies Modern Epidemiology. Fourth edition ed. Lippincott Williams & Wilkins Philadelphia; 2021.
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215. doi:10.1093/nar/16.3.1215
FEDERATIE VAN NEDERLANDSE TROMBOSEDIENSTEN "De kunst van het doseren ‐ Richtlijn, leidraad en informatie voor het doseren van vitamine K‐ antagonist ", Hoofdstuk 10, Bloedingscomplicaties. https://s3.eu‐central‐1.amazonaws.com/storage.topsite.nl/fnt.nl/uploads/docs/De‐kunst‐van‐het‐doseren/FNT_KvhD_juli‐2023.pdf
Johnson JA, Caudle KE, Gong L, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics‐guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102(3):397‐404. doi:10.1002/cpt.668
Lash TL, VanderWeele TJ, Haneause S, Rothman KJ. Chapter 12: Confounding and Confounders. Modern Epidemiology. Fourth edition ed. Lippincott Williams & Wilkins Philadelphia; 2021.
Yang J, Chen Y, Li X, et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin‐treated patients: a systematic review and meta‐analysis. Int J Cardiol. 2013;168(4):4234‐4243. doi:10.1016/j.ijcard.2013.07.151
Ufer M. Comparative pharmacokinetics of vitamin K antagonists. Clin Pharmacokinet. 2005;44(12):1227‐1246. doi:10.2165/00003088-200544120-00003
Shendre A, Brown TM, Liu N, et al. Race‐specific influence of CYP4F2 on dose and risk of hemorrhage among warfarin users. Pharmacotherapy. 2016;36(3):263‐272. doi:10.1002/phar.1717
van Schie RM, Aoussar A, van der Meer FJ, de Boer A, Maitland‐van der Zee AH. Evaluation of the effects of single‐nucleotide polymorphisms in CYP3A4 and CYP4F2 on stable phenprocoumon and acenocoumarol maintenance doses. J Thromb Haemost. 2013;11(6):1200‐1203. doi:10.1111/jth.12195
Danese E, Raimondi S, Montagnana M, et al. Effect of CYP4F2, VKORC1, and CYP2C9 in influencing coumarin dose: A single‐patient data meta‐analysis in more than 15,000 individuals. Clin Pharmacol Ther. 2019;105(6):1477‐1491. doi:10.1002/cpt.1323
Danese E, Montagnana M, Johnson JA, et al. Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta‐analysis. Clin Pharmacol Ther. 2012;92(6):746‐756. doi:10.1038/clpt.2012.184
Zhang JE, Jorgensen AL, Alfirevic A, et al. Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet Genomics. 2009;19(10):781‐789. doi:10.1097/FPC.0b013e3283311347 PubMed PMID: 19741565.
Sridharan K, Sivaramakrishnan G. A network meta‐analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype‐based warfarin dosing strategies compared to traditional. J Clin Pharm Ther. 2021;46(3):640‐648.
Sychev DA, Rozhkov AV, Kazakov RE, Ananichuk AV. The impact of CYP4F2, ABCB1, and GGCX polymorphisms on bleeding episodes associated with acenocoumarol in Russian patients with atrial fibrillation. Drug Metab Pers Ther. 2016;31(3):173‐178. doi:10.1515/dmpt-2016-0014
Roden DM, McLeod HL, Relling MV, et al. Pharmacogenomics. Lancet (London, England). 2019;394(10197):521‐532. doi:10.1016/S0140-6736(19)31276-0
Yang T, Zhou Y, Chen C, Lu M, Ma L, Cui Y. Genotype‐guided dosing versus conventional dosing of warfarin: a meta‐analysis of 15 randomized controlled trials. J Clin Pharm Ther. 2019;44(2):197‐208. doi:10.1111/jcpt.12782
Stergiopoulos K, Brown DL. Genotype‐guided vs clinical dosing of warfarin and its analogues: meta‐analysis of randomized clinical trials. JAMA Intern Med. 2014;174(8):1330‐1338. doi:10.1001/jamainternmed.2014.2368
Franchini M, Mengoli C, Cruciani M, Bonfanti C, Mannucci PM. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta‐analysis. J Thromb Haemost. 2014;12(9):1480‐1487. doi:10.1111/jth.12647
Belley‐Cote EP, Hanif H, D'Aragon F, et al. Genotype‐guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. Thromb Haemost. 2015;114(10):768‐777.
Wang X, Tang B, Zhou M, et al. Efficacy and safety of genotype‐guided warfarin dosing versus non‐genotype‐guided warfarin dosing strategies: a systematic review and meta‐analysis of 27 randomized controlled trials. Thromb Res. 2022;210:42‐52. doi:10.1016/j.thromres.2021.12.023
Holbrook A, Schulman S, Witt DM, et al. Evidence‐based Management of Anticoagulant Therapy. Chest. 2012;141(2):e152S‐e184S. doi:10.1378/chest.11-2295
Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association (KNMP) Dutch Pharmacogenetics Working Group guidelines update November 2021. https://www.knmp.nl/sites/default/files/2023‐11/Recommendation_text_pharmacogenetics_20211109.pdf
van der Wouden CH, van Rhenen MH, Jama WOM, et al. Development of the PGx‐passport: a panel of actionable germline genetic variants for pre‐Emptive pharmacogenetic testing. Clini Pharmacol Ther. 2019;106(4):866‐873. doi:10.1002/cpt.1489
Swen JJ, van der Wouden CH, Manson LEN, et al. A 12‐gene pharmacogenetic panel to prevent adverse drug reactions: an open‐label, multicentre, controlled, cluster‐randomised crossover implementation study. Lancet. 2023;401(10374):347‐356. doi:10.1016/S0140-6736(22)01841-4